Overview
DEKA Research & Development Corp. is a leading engineering R&D lab in Manchester, New Hampshire that develops a wide range of practical technologies and devices. It operates by interdisciplinary teams of engineers, machinists, designers, and technicians who take ambitious ideas and turn them into tangible products using advanced design and manufacturing methods. The company differentiates itself through its culture of hands-on experimentation, diverse project portfolio, and a track record of bringing to market or translating ideas into real-world applications. Its goal is to create technologies with a positive, lasting impact on people’s lives by solving meaningful problems.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA cleared twiist for adults with insulin-treated Type 2 diabetes on October 16, 2026.
- Sequel launched twiist nationally in March 2026, creating recurring royalties for DEKA.
- The July 2026 war.gov project funded DEKA Integrated Solutions' microneedle manufacturing work.
What critics are saying
- DEKA depends on Sequel Med Tech; a commercialization slip cuts royalties quickly.
- The 2024 Emergex collaboration still lacks a commercial product, signaling slow monetization.
- If Sequel's twiist adoption stalls, DEKA loses its main diabetes revenue engine.
What makes DEKA Research & Development Corp. unique
- DEKA's FDA-cleared twiist platform spans Type 1 and Type 2 diabetes, through October 2026.
- Its iiSure Infusion Set won FDA clearance June 3, 2026, extending pump ecosystem control.
- DEKA's intradermal applicator attracts biotech and DOD interest, including Emergex and July 2026.
Help us improve and share your feedback! Did you find this helpful?